Navigation Links
Biopharmaceutical Companies Transform Clinical Trial Strategies for Success in Global Marketplace
Date:4/13/2013

CHAPEL HILL, N.C., April 13, 2013 /PRNewswire/ -- Pharmaceutical companies in North America and Europe have recently been faced with two major concerns: clinical costs are continuing to rise and sales are either rising a little or not at all. In emerging markets, organizations are experiencing lower clinical costs and rapidly rising sales. Although mature markets still represent a majority of sales, it is clear that emerging markets offer significant cost savings and important future sales.

While there are many advantages that come along with expanding into these emerging markets, large countries like China and India are now requiring local clinical trials to win regulatory approvals to market products in those countries. Despite these obstacles, pharmaceutical organizations must evaluate the necessity of expanding their clinical programs into emerging markets in order to cut costs and boost sales.

In order to help biopharma organizations set a strategic direction for conducting clinical trial activities in emerging regions of the world, Best Practices, LLC conducted a primary research report. The report, Clinical Affairs Excellence: Benchmarking Clinical Trial Strategies for Pharmaceutical Success in a Global Marketplace, analyzes factors associated with outsourcing clinical trial activities – including cost, staffing, and quality – to help leadership evaluate the organization's approach to outsourcing relative to other market leaders.

Key study topics include:

  • Pharmaceutical presence in emerging markets
  • Evaluating resource levels
  • Outsourcing for key clinical trials
  • Benefits of clinical outsourcing

These research findings provide industry metrics and insights that can serve as a reference point for clinical leaders when formulating a strategic approach for engaging emerging regions in clinical affairs activities. The performance benchmark and field research harvested scores of insights and observations from seven clinical leaders at six pharmaceutical companies.

To review highlights of the full report, download a complimentary summary containing selected metrics and key findings, visit http://www.best-in-class.com/rr1212.htm.

For more information on this study or other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
4. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
7. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
8. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
10. Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
11. The Thousand-Year Business Model for a Modern Biopharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... --  Divoti USA will engrave and process all ... the latest FDA requirements, which stipulates new criteria regarding medical device ... of Medical ID jewelry such as Medical ID Bracelets, can rest ... terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):